Is TCMD a good stock to buy right now?

Based on our 6-factor quantitative model, TACTILE SYSTEMS TECHNOLOGY INC (TCMD) receives a "Hold" rating with a composite score of 48.5/100. It is ranked #1,659 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 59/100, Momentum 65/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for TCMD?

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) has a "Hold" rating and 3-star score. The composite score of 48.5 ranks it #1,659 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is TCMD in?

TACTILE SYSTEMS TECHNOLOGY INC operates in the Healthcare sector (Medical Equipment industry) with a market cap of $591 million. It is classified as a small-cap stock.

Does TCMD pay a dividend?

TCMD does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is TCMD's P/E ratio?

TCMD has a trailing P/E ratio of 40.21x. The Healthcare sector average is 23.6x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is TCMD?

TCMD's quality factor score is 50/100. Gross margin: 74.8%. ROE: 6.2% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is TCMD valued compared to peers?

TCMD's value factor score is 59/100 (higher = cheaper). Key multiples: P/E 40.2x, EV/EBITDA 31.6x. Valuation is roughly in line with peers.

What is TCMD's debt level?

TCMD's debt-to-equity ratio is 0%. Sector average: 32%. Low leverage suggests conservative financial management.

TCMD has a beta of 0.97, meaning it tracks the market. Stability score: 52/100.

Does TCMD have high short interest?

TCMD's short interest factor score is 6/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

TCMD Stock Analysis: Top Small-Cap Hold (Score 48.5/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
TCMD	-2.21%	-4.76%	-16.65%	-19.21%	+74.85%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-2.15%	-8.36%	-16.99%	-18.85%	+45.33%	-	-	-
Alpha vs Sector	-0.86%	-5.10%	-12.84%	-14.37%	+65.64%	-	-	-

Metric	TCMD	Benchmark
P/E Ratio	40.2x	+70%
EV/EBITDA	31.6x	+399%
Price / Book	2.5x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
TCMD TACTILE SYSTEMS TECHNOLOGY INC	49	50	59	65	40.2x	6.2%	74.8%	4.0%	17.1%	0.0x	$591M

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.7%	0.8%	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%
Operating Margin %	0.0%	0.1%	0.1%	0.1%	-0.1%	-0.0%	-0.0%	0.1%	0.0%	0.0%	0.1%
EBITDA Margin %	0.1%	0.1%	0.1%	0.1%	-0.1%	-0.0%	0.0%	0.1%	0.0%	0.1%	0.1%
Net Margin %	0.0%	0.1%	0.1%	0.1%	-0.1%	-0.1%	-0.0%	0.1%	0.0%	0.1%	0.0%
FCF Margin %	-	-	-	-	-	-	0.4%	-1.5%	3.3%	0.4%	7.4%
ROE %	0.1%	0.1%	0.1%	0.1%	-0.1%	-0.1%	-0.0%	0.1%	0.1%	0.1%	0.0%
ROA %	0.0%	0.1%	0.1%	0.1%	-0.1%	-0.0%	-0.0%	0.1%	0.1%	0.1%	0.0%
ROIC %	0.0%	10.6%	8.1%	7.4%	-8.3%	-1.1%	-3.7%	9.2%	3.4%	6.3%	11.7%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.7%

0.8%

0.7%

Operating Margin %

0.0%

0.1%

-0.1%

-0.0%

0.1%

0.0%

0.1%

EBITDA Margin %

0.1%

-0.1%

-0.0%

0.0%

0.1%

0.0%

0.1%

Net Margin %

0.0%

0.1%

-0.1%

-0.0%

0.1%

0.0%

0.1%

0.0%

FCF Margin %

0.4%

-1.5%

3.3%

0.4%

7.4%

ROE %

0.1%

-0.1%

-0.0%

0.1%

0.0%

ROA %

0.0%

0.1%

-0.1%

-0.0%

0.1%

0.0%

ROIC %

0.0%

10.6%

8.1%

7.4%

-8.3%

-1.1%

-3.7%

9.2%

3.4%

6.3%

11.7%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$299M	$330M	$293M	$274M	$247M	$208M	$187M	$189M	$144M	$109M	$85M	$63M
	—	$79M	$76M	$79M	$71M	$60M	—	—	—	—	—	—
	$224M	$250M	$217M	$195M	$176M	$148M	$133M	$134M	$102M	$80M	$62M	$46M
Gross Margin	74.8%	75.9%	74.0%	71.1%	71.3%	71.2%	71.0%	70.8%	71.1%	73.5%	72.9%	73.1%
	—	$8M	$9M	$8M	$7M	$6M	$5M	$5M	$5M	$5M	$4M	$4M
Depreciation	—	—	—	—	—	—	$3M	$3M	$4M	$2M	$799K	$827K
Total Operating Expenses	—	$221M	$195M	$177M	$189M	$150M	—	—	—	—	—	—
	$17M	$29M	$22M	$18M	-$13M	-$2M	-$4M	$10M	$3M	$4M	$4M	$3M
EBIT	$17M	$29M	$22M	$18M	-$13M	-$2M	-$4M	$10M	$3M	$4M	$4M	$3M
EBITDA	$17M	$29M	$22M	$18M	-$13M	-$2M	$442K	$14M	$7M	$6M	$5M	$4M
Operating Margin	5.0%	8.9%	7.6%	6.6%	-5.2%	-0.9%	-1.9%	5.5%	2.1%	3.6%	5.1%	5.5%
EBITDA Margin	5.8%	8.9%	7.6%	6.6%	-5.2%	-0.8%	0.2%	7.6%	4.9%	5.5%	6.0%	6.5%
	—	$31M	$23M	$16M	-$15M	-$2M	—	—	—	—	—	—
Income Tax Expense	—	$12M	$7M	-$13M	$2M	$10M	-$2M	$158K	-$3M	-$2M	$1M	$2M
	$14M	$19M	$17M	$29M	-$18M	-$12M	-$620K	$11M	$7M	$6M	$3M	$1M
Net Margin	4.0%	5.8%	5.8%	10.4%	-7.2%	-5.7%	-0.3%	5.8%	4.6%	5.4%	3.4%	2.2%
	$0.83	$0.83	$0.71	$1.24	$-0.89	$-0.60	-	-	-	-	-	-
Diluted EPS	$0.83	$0.82	$0.70	$1.23	$-0.89	$-0.60	-	-	-	-	-	-
Weighted Avg Basic	—	23M	24M	23M	20M	20M	—	—	—	—	—	—
Weighted Avg Diluted	—	23M	24M	23M	20M	20M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$299M

$330M

$293M

$274M

$247M

$208M

$187M

$189M

$144M

$109M

$85M

$63M

—

$79M

$76M

$79M

$71M

$60M

—

$224M

$250M

$217M

$195M

$176M

$148M

$133M

$134M

$102M

$80M

$62M

$46M

Gross Margin

74.8%

75.9%

74.0%

71.1%

71.3%

71.2%

71.0%

70.8%

71.1%

73.5%

72.9%

73.1%

—

$8M

$9M

$8M

$7M

$6M

$5M

$4M

Depreciation

—

$3M

$4M

$2M

$799K

$827K

Total Operating Expenses

—

$221M

$195M

$177M

$189M

$150M

—

$17M

$29M

$22M

$18M

-$13M

-$2M

-$4M

$10M

$3M

$4M

$3M

EBIT

$17M

$29M

$22M

$18M

-$13M

-$2M

-$4M

$10M

$3M

$4M

$3M

EBITDA

$17M

$29M

$22M

$18M

-$13M

-$2M

$442K

$14M

$7M

$6M

$5M

$4M

Operating Margin

5.0%

8.9%

7.6%

6.6%

-5.2%

-0.9%

-1.9%

5.5%

2.1%

3.6%

5.1%

5.5%

EBITDA Margin

5.8%

8.9%

7.6%

6.6%

-5.2%

-0.8%

0.2%

7.6%

4.9%

5.5%

6.0%

6.5%

—

$31M

$23M

$16M

-$15M

-$2M

—

Income Tax Expense

—

$12M

$7M

-$13M

$2M

$10M

-$2M

$158K

-$3M

-$2M

$1M

$2M

$14M

$19M

$17M

$29M

-$18M

-$12M

-$620K

$11M

$7M

$6M

$3M

$1M

Net Margin

4.0%

5.8%

10.4%

-7.2%

-5.7%

-0.3%

5.8%

4.6%

5.4%

3.4%

2.2%

$0.83

$0.71

$1.24

$-0.89

$-0.60

Diluted EPS

$0.83

$0.82

$0.70

$1.23

$-0.89

$-0.60

Weighted Avg Basic

—

23M

24M

23M

20M

—

Weighted Avg Diluted

—

23M

24M

23M

20M

—

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does TACTILE SYSTEMS TECHNOLOGY INC Do?

Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota. TACTILE SYSTEMS TECHNOLOGY INC (TCMD) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Daniel L. Reuvers and employs approximately 980 people, headquartered in MINNEAPOLIS, Minnesota. With a market capitalization of $591M, TCMD is one of the notable companies in the Healthcare sector.

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) Stock Rating — Hold (April 2026)

As of April 2026, TACTILE SYSTEMS TECHNOLOGY INC receives a Hold rating with a composite score of 48.5/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.TCMD ranks #1,659 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, TACTILE SYSTEMS TECHNOLOGY INC ranks #153 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TCMD Stock Price and 52-Week Range

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) currently trades at $23.96. The 52-week high for TCMD is $37.77, which means the stock is currently trading -36.6% from its annual peak. The 52-week low is $8.61, putting the stock 178.3% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is TCMD Overvalued or Undervalued? — Valuation Analysis

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) carries a value factor score of 59/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 40.21x, compared to the Healthcare sector average of 23.63x — a premium of 70%. The price-to-book ratio stands at 2.50x, versus the sector average of 2.75x. The price-to-sales ratio is 1.83x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, TCMD trades at 31.65x EV/EBITDA, versus 6.34x for the sector.

Overall, TCMD's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

TACTILE SYSTEMS TECHNOLOGY INC Profitability — ROE, Margins, and Quality Score

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 6.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 5.0% versus the sector average of -33.1%.

On a margin basis, TACTILE SYSTEMS TECHNOLOGY INC reports gross margins of 74.8%, compared to 71.5% for the sector. The operating margin is 5.0% (sector: -66.1%). Net profit margin stands at 4.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 17.1% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

TCMD Debt, Balance Sheet, and Financial Health

TACTILE SYSTEMS TECHNOLOGY INC has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.03x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $66M.

TCMD has a beta of 0.97, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for TACTILE SYSTEMS TECHNOLOGY INC is 52/100, reflecting average volatility within the normal range for its sector.

TACTILE SYSTEMS TECHNOLOGY INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, TACTILE SYSTEMS TECHNOLOGY INC reported revenue of $299M and earnings per share (EPS) of $0.83. Net income for the quarter was $14M. Gross margin was 74.8%. Operating income came in at $17M.

In FY 2025, TACTILE SYSTEMS TECHNOLOGY INC reported revenue of $330M and earnings per share (EPS) of $0.83. Net income for the quarter was $19M. Gross margin was 75.9%. Revenue grew 12.5% year-over-year compared to FY 2024. Operating income came in at $29M.

In Q3 2025, TACTILE SYSTEMS TECHNOLOGY INC reported revenue of $86M and earnings per share (EPS) of $0.37. Net income for the quarter was $8M. Gross margin was 75.8%. Revenue grew 17.3% year-over-year compared to Q3 2024. Operating income came in at $11M.

In Q2 2025, TACTILE SYSTEMS TECHNOLOGY INC reported revenue of $79M and earnings per share (EPS) of $0.14. Net income for the quarter was $3M. Gross margin was 74.5%. Revenue grew 7.8% year-over-year compared to Q2 2024. Operating income came in at $4M.

Over the past 8 quarters, TACTILE SYSTEMS TECHNOLOGY INC has demonstrated a growth trajectory, with revenue expanding from $73M to $299M. Investors analyzing TCMD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TCMD Dividend Yield and Income Analysis

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TCMD Momentum and Technical Analysis Profile

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) has a momentum factor score of 65/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 6/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

TCMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, TACTILE SYSTEMS TECHNOLOGY INC (TCMD) ranks #153 out of 838 stocks based on the Blank Capital composite score. This places TCMD in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TCMD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TCMD vs S&P 500 (SPY) comparison to assess how TACTILE SYSTEMS TECHNOLOGY INC stacks up against the broader market across all factor dimensions.

TCMD Next Earnings Date

No upcoming earnings date has been announced for TACTILE SYSTEMS TECHNOLOGY INC (TCMD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TCMD? — Investment Thesis Summary

TACTILE SYSTEMS TECHNOLOGY INC presents a balanced picture with arguments on both sides. Price momentum is positive at 65/100, suggesting the trend favors buyers.

In summary, TACTILE SYSTEMS TECHNOLOGY INC (TCMD) earns a Hold rating with a composite score of 48.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TCMD stock.

Related Resources for TCMD Investors

Explore more research and tools: TCMD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TCMD head-to-head with peers: TCMD vs AZN, TCMD vs SLGL, TCMD vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

The $300 Million Medical Device Company That a Quant Model Ranks Number One in America

Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes

Wall Street Analysts See a 41.11% Upside in Tactile Systems Technology (TCMD): Can the Stock Really Move This High?

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does TACTILE SYSTEMS TECHNOLOGY INC Do?

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) Stock Rating — Hold (April 2026)

TCMD Stock Price and 52-Week Range

Is TCMD Overvalued or Undervalued? — Valuation Analysis

TACTILE SYSTEMS TECHNOLOGY INC Profitability — ROE, Margins, and Quality Score

TCMD Debt, Balance Sheet, and Financial Health

TACTILE SYSTEMS TECHNOLOGY INC Revenue and Earnings History — Quarterly Trend

TCMD Dividend Yield and Income Analysis

TCMD Momentum and Technical Analysis Profile

TCMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

TCMD Next Earnings Date

Should You Buy TCMD? — Investment Thesis Summary

Related Resources for TCMD Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

The $300 Million Medical Device Company That a Quant Model Ranks Number One in America

Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes

Wall Street Analysts See a 41.11% Upside in Tactile Systems Technology (TCMD): Can the Stock Really Move This High?